World’s First Transforming Coronary Artery Implant Designed to Restore Vessel Physiology and Function

About DynamX Coronary Bioadaptor Scaffold

DynamX Bioadaptor is the first coronary scaffold technology designed to unlock the scaffold, uncage the vessel, and restore and sustain normal vessel motion and function after percutaneous coronary intervention (PCI) by maintaining dynamic support of the diseased vessel after its uncaging.

With this unique mechanism of action (MOA), it addresses the shortcomings of drug eluting stents and bioresorbable scaffolds (BRS) while delivering low clinical event rates.

The DynamX Coronary Bioadaptor System is CE marked. Not available for sale in the USA.

About Elixir Medical

Elixir Medical Corporation, a privately-held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheral artery disease. The company’s technologies have multiple applications across the cardiovascular space capable of delivering improved clinical outcomes for millions of patients.

Visit Elixir at elixirmedical.com and on LinkedIn and Twitter.

Latest news

Related news